JP2010535012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535012A5 JP2010535012A5 JP2009551102A JP2009551102A JP2010535012A5 JP 2010535012 A5 JP2010535012 A5 JP 2010535012A5 JP 2009551102 A JP2009551102 A JP 2009551102A JP 2009551102 A JP2009551102 A JP 2009551102A JP 2010535012 A5 JP2010535012 A5 JP 2010535012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- egfr
- composition
- separate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 102000045108 human EGFR Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700317 | 2007-03-01 | ||
| DKPA200700317 | 2007-03-01 | ||
| US90477307P | 2007-03-05 | 2007-03-05 | |
| US60/904,773 | 2007-03-05 | ||
| DKPA200701016 | 2007-07-10 | ||
| DKPA200701016 | 2007-07-10 | ||
| US92972707P | 2007-07-11 | 2007-07-11 | |
| US60/929,727 | 2007-07-11 | ||
| PCT/DK2008/050047 WO2008104183A2 (en) | 2007-03-01 | 2008-02-27 | Recombinant anti-epidermal growth factor receptor antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535012A JP2010535012A (ja) | 2010-11-18 |
| JP2010535012A5 true JP2010535012A5 (enExample) | 2011-04-14 |
| JP5726417B2 JP5726417B2 (ja) | 2015-06-03 |
Family
ID=39495833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551102A Active JP5726417B2 (ja) | 2007-03-01 | 2008-02-27 | 組み換え抗上皮成長因子受容体抗体組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7887805B2 (enExample) |
| EP (2) | EP2132229B1 (enExample) |
| JP (1) | JP5726417B2 (enExample) |
| KR (2) | KR101676622B1 (enExample) |
| CN (2) | CN101675075B (enExample) |
| AU (1) | AU2008221118B2 (enExample) |
| BR (1) | BRPI0808551B1 (enExample) |
| CA (1) | CA2676049C (enExample) |
| DK (1) | DK2132229T3 (enExample) |
| ES (1) | ES2582386T3 (enExample) |
| HK (1) | HK1197252A1 (enExample) |
| IL (2) | IL199725A (enExample) |
| MX (2) | MX2009008909A (enExample) |
| NZ (2) | NZ597466A (enExample) |
| PL (1) | PL2132229T3 (enExample) |
| RU (1) | RU2013119724A (enExample) |
| TW (1) | TWI426083B (enExample) |
| WO (1) | WO2008104183A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ597466A (en) | 2007-03-01 | 2013-08-30 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
| JP5669397B2 (ja) * | 2007-03-01 | 2015-02-12 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | 同族抗体をクローニングするための方法 |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| EP2190878A1 (en) * | 2007-09-06 | 2010-06-02 | Genmab A/S | Novel methods and antibodies for treating cancer |
| WO2009086411A2 (en) * | 2007-12-27 | 2009-07-09 | Abbott Laboratories | Negative mimic antibody for use as a blocking reagent in bnp immunoassays |
| WO2010022738A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
| EP2331577B1 (en) * | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| AU2009301505A1 (en) * | 2008-10-06 | 2010-04-15 | Symphogen A/S | Method for identifying and selecting drug candidates for combinatorial drug products |
| FR2942928B1 (fr) | 2009-03-03 | 2011-04-01 | Alcatel Lucent | Procede et systeme de gestion multicriteres de notifications de presence |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| EP2486411A2 (en) | 2009-10-09 | 2012-08-15 | Symphogen A/S | Multiplex quantitation of individual recombinant proteins in a mixture by signature peptides and mass spectrometry |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| EP3085387A1 (en) | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| CA2798273A1 (en) * | 2010-05-04 | 2011-11-10 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2011140151A1 (en) * | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
| CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| KR20140008308A (ko) * | 2010-10-29 | 2014-01-21 | 이뮤노젠 아이엔씨 | 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| KR101862832B1 (ko) * | 2010-11-01 | 2018-05-30 | 심포젠 에이/에스 | Ｐａｎ―ｈｅｒ 항체 조성물 |
| CA2858350A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| US10570211B2 (en) | 2011-01-24 | 2020-02-25 | Gilead Sciences, Inc. | Antibodies selective for cells presenting EGFR at high density |
| CN108220297A (zh) | 2011-03-09 | 2018-06-29 | 细胞信号科技公司 | 用于生成单克隆抗体的方法和试剂 |
| BR112013022882A2 (pt) | 2011-03-11 | 2016-12-20 | Merrimack Pharmaceuticals Inc | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
| JP2014509593A (ja) | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
| US20120258502A1 (en) * | 2011-04-08 | 2012-10-11 | Vinod Pandiripally | Method of producing recombinant plasmid dna using substantially solid growth medium |
| US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| KR20140105765A (ko) | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법 |
| WO2013106489A1 (en) * | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| HK1202431A1 (en) | 2012-05-02 | 2015-10-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| US20140065655A1 (en) * | 2012-09-05 | 2014-03-06 | Scivax Corporation | Screening method for substance acting on maintenance of epithelial properties of cell |
| US20150293105A1 (en) * | 2012-10-26 | 2015-10-15 | The University Of Queensland | Methods for classifying tumors and uses therefor |
| CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| US9856319B2 (en) * | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| CN104059148B (zh) * | 2013-03-18 | 2016-09-07 | 回而生医药科技（北京）有限公司 | 人源化抗人表皮生长因子受体抗体及其应用 |
| WO2015038984A2 (en) * | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CN106170299A (zh) * | 2014-01-22 | 2016-11-30 | 小利兰斯坦福大学托管委员会 | 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物 |
| GB201402591D0 (en) | 2014-02-14 | 2014-04-02 | Memo Therapeutics Ag | Method for recovering two or more genes, or gene products, encoding an immunoreceptor |
| US20170176419A1 (en) * | 2014-03-26 | 2017-06-22 | Siemens Healthcare Diagnostics Inc. | Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| WO2016065456A1 (en) * | 2014-10-31 | 2016-05-06 | Formation Biologics Inc. | Egfr antibody-based combination therapy |
| US10765699B2 (en) | 2015-02-06 | 2020-09-08 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| EP3286219A1 (en) | 2015-04-24 | 2018-02-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies |
| AU2017235450A1 (en) | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| JP7301540B2 (ja) * | 2016-05-26 | 2023-07-03 | チールー ピュージェット サウンド バイオセラピューティクス コーポレイション | 抗体の混合物 |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| RU2019123063A (ru) * | 2016-12-23 | 2021-01-26 | Вистерра, Инк. | Связывающие полипептиды и способы их получения |
| EP3585814B1 (en) * | 2017-02-22 | 2025-12-10 | University of Saskatchewan | Egfr-binding agents and uses thereof |
| WO2018166119A1 (zh) * | 2017-03-14 | 2018-09-20 | 北京伟峰益民科技有限公司 | 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用 |
| CN111247241A (zh) | 2017-08-10 | 2020-06-05 | 新加坡国立大学 | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 |
| WO2019043059A1 (en) | 2017-08-30 | 2019-03-07 | Symphogen A/S | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| EP3743109A4 (en) * | 2018-01-25 | 2021-11-10 | Cullinan Mica Corp. | MICA / B ANTIBODIES AND METHOD OF USE |
| EP3784776A4 (en) | 2018-05-23 | 2022-01-26 | National University of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US12162747B2 (en) | 2018-12-03 | 2024-12-10 | X-Celeprint Limited | Enclosed cavity structures |
| US11274035B2 (en) | 2019-04-24 | 2022-03-15 | X-Celeprint Limited | Overhanging device structures and related methods of manufacture |
| US10456776B1 (en) | 2019-02-21 | 2019-10-29 | King Saud University | Method of fabricating a photocatalyst for water splitting |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| CN111018990A (zh) * | 2020-02-10 | 2020-04-17 | 张喜田 | 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用 |
| KR20240067131A (ko) | 2021-10-04 | 2024-05-16 | 르 라보레또레 쎄르비에르 | Nkg2a를 표적화하는 암 요법 |
| AR127893A1 (es) | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
| WO2026082020A1 (zh) * | 2024-10-15 | 2026-04-23 | 一线医药（杭州）有限公司 | 双特异性抗体和药物偶联物及其用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5459061A (en) | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| SK281143B6 (sk) * | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| CA2120745A1 (en) | 1992-06-30 | 1994-01-06 | Philip G. Kasprzyk | A combination of anti-erbb-2 monoclonal antibodies and method of using |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US7201905B2 (en) | 2000-03-23 | 2007-04-10 | Greenville Hospital System | Bi-functional cancer treatment agents |
| ES2259030T3 (es) * | 2000-05-19 | 2006-09-16 | Scancell Limited | Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico. |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| KR20030074839A (ko) * | 2001-02-19 | 2003-09-19 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체 |
| US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| WO2002100348A2 (en) | 2001-06-13 | 2002-12-19 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| AU2002326531A1 (en) | 2001-08-03 | 2003-02-17 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
| AU2003211342A1 (en) | 2002-03-01 | 2003-09-16 | Japan Envirochemicals, Ltd. | Proteins capable of binding to environmental hormones and process for producing the same |
| AU2003236649A1 (en) | 2002-05-15 | 2003-12-02 | Falko Fend | Egf receptor antagonists in the treatment of gastric cancer |
| EP1575491A4 (en) | 2002-05-20 | 2006-09-27 | Abgenix Inc | TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| EP2314629B2 (en) | 2002-07-18 | 2022-11-16 | Merus N.V. | Recombinant production of mixtures of antibodies |
| ES2533963T3 (es) * | 2002-10-10 | 2015-04-16 | Merck Patent Gmbh | Composiciones farmacéuticas dirigidas a receptores Erb-B1 |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
| CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| US7655751B2 (en) * | 2004-01-23 | 2010-02-02 | Green Peptide Co., Ltd. | Epidermal growth factor receptor-derived peptides |
| US20110142822A1 (en) | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| PL1787126T3 (pl) | 2004-07-20 | 2010-03-31 | Symphogen As | Sposób charakteryzowania poliklonalnej linii komórkowej |
| MX2007000644A (es) | 2004-07-20 | 2007-03-28 | Symphogen As | Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion. |
| ES2710439T3 (es) | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
| US20070009972A1 (en) | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
| KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
| CN101208354A (zh) | 2005-02-24 | 2008-06-25 | 安姆根有限公司 | 表皮生长因子受体突变 |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| WO2006110478A2 (en) | 2005-04-11 | 2006-10-19 | Novartis Ag | Mutations and polymorphisms of epidermal growth factor receptor |
| KR20080003422A (ko) | 2005-04-14 | 2008-01-07 | 메르크 파텐트 게엠베하 | 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료 |
| CN101277716A (zh) | 2005-04-27 | 2008-10-01 | 回而生医药科技有限公司 | 治疗癌症的抗体 |
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US20070036786A1 (en) * | 2005-07-11 | 2007-02-15 | Nadine Tuaillon | Method of treating autoimmune disease using humanized anti-CD16A antibodies |
| JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| MX2008011280A (es) | 2006-03-06 | 2008-09-12 | Symphogen As | Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio. |
| NZ597466A (en) | 2007-03-01 | 2013-08-30 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
| JP5669397B2 (ja) | 2007-03-01 | 2015-02-12 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | 同族抗体をクローニングするための方法 |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| EP2331577B1 (en) * | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US9155802B2 (en) * | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
-
2008
- 2008-02-27 NZ NZ597466A patent/NZ597466A/xx not_active IP Right Cessation
- 2008-02-27 CA CA2676049A patent/CA2676049C/en active Active
- 2008-02-27 NZ NZ578943A patent/NZ578943A/xx unknown
- 2008-02-27 CN CN200880006835.0A patent/CN101675075B/zh active Active
- 2008-02-27 KR KR1020097020519A patent/KR101676622B1/ko active Active
- 2008-02-27 WO PCT/DK2008/050047 patent/WO2008104183A2/en not_active Ceased
- 2008-02-27 DK DK08706941.5T patent/DK2132229T3/en active
- 2008-02-27 EP EP08706941.5A patent/EP2132229B1/en active Active
- 2008-02-27 PL PL08706941.5T patent/PL2132229T3/pl unknown
- 2008-02-27 KR KR1020167031076A patent/KR101805140B1/ko not_active Expired - Fee Related
- 2008-02-27 AU AU2008221118A patent/AU2008221118B2/en active Active
- 2008-02-27 CN CN201410211600.2A patent/CN104151430A/zh active Pending
- 2008-02-27 MX MX2009008909A patent/MX2009008909A/es active IP Right Grant
- 2008-02-27 ES ES08706941.5T patent/ES2582386T3/es active Active
- 2008-02-27 JP JP2009551102A patent/JP5726417B2/ja active Active
- 2008-02-27 EP EP13187455.4A patent/EP2725036B1/en not_active Not-in-force
- 2008-02-27 MX MX2011011163A patent/MX338151B/es unknown
- 2008-02-27 BR BRPI0808551-0A patent/BRPI0808551B1/pt active IP Right Grant
- 2008-02-29 US US12/074,056 patent/US7887805B2/en active Active
- 2008-02-29 TW TW097107005A patent/TWI426083B/zh active
-
2009
- 2009-07-07 IL IL199725A patent/IL199725A/en active IP Right Grant
-
2010
- 2010-11-12 US US12/945,495 patent/US20110129855A1/en not_active Abandoned
- 2010-11-12 US US12/945,527 patent/US8414896B2/en active Active
-
2011
- 2011-12-08 IL IL216850A patent/IL216850A/en active IP Right Grant
-
2013
- 2013-04-26 RU RU2013119724/10A patent/RU2013119724A/ru not_active Application Discontinuation
-
2014
- 2014-10-29 HK HK14110853.9A patent/HK1197252A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022061992A5 (enExample) | ||
| TWI659969B (zh) | 一種抗ｐｄ－１的單株抗體及其獲得方法 | |
| JP2018502050A5 (enExample) | ||
| JP2020023523A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| JP2021524268A5 (enExample) | ||
| JP2017536341A5 (enExample) | ||
| JP2021508469A5 (enExample) | ||
| EP4039705A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| JP2019532625A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2009535021A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2009502171A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| JP2012530496A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2022513420A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2012500815A5 (enExample) | ||
| JP2021524275A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| JP2011514139A5 (enExample) | ||
| JP2014530001A5 (enExample) |